| 1 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang‐Gillam et al. · The Lancet
|
29 Nov 2015 |
1,232 |
| 2 |
Systems biology and combination therapy in the quest for clinical efficacy
Jonathan B. Fitzgerald, Birgit Schoeberl, Ulrik B. Nielsen et al. · Nature Chemical Biology
|
18 Aug 2006 |
591 |
| 3 |
Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics
Manu P. Kumar, Jinyan Du, Georgia Lagoudas et al. · Cell Reports
Open access |
Nov 2018 |
478 |
| 4 |
Input–output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data
William W. Chen, Birgit Schoeberl, Paul Jasper et al. · Molecular Systems Biology
Open access |
20 Jan 2009 |
407 |
| 5 |
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer
Helen Lee, Anthony Frank Shields, Barry Alan Siegel et al. · Clinical Cancer Research
Open access |
15 Mar 2017 |
386 |
| 6 |
Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis
Birgit Schoeberl, Emily A. Pace, Jonathan B. Fitzgerald et al. · Science Signaling
|
30 Jun 2009 |
369 |
| 7 |
Lessons Learned from Quantitative Dynamical Modeling in Systems Biology
Andreas Raue, Marcel Schilling, Julie Bachmann et al. · PLoS ONE
Open access |
30 Sep 2013 |
364 |
| 8 |
Estimation of immune cell content in tumour tissue using single-cell RNA-seq data
Max Schelker, Sonia Feau, Jinyan Du et al. · Nature Communications
Open access |
5 Dec 2017 |
348 |
| 9 |
Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
Charlotte Fenton McDonagh, Alexandra Huhalov, Brian D. Harms et al. · Molecular Cancer Therapeutics
|
16 Jan 2012 |
277 |
| 10 |
Data2Dynamics: a modeling environment tailored to parameter estimation in dynamical systems
Andreas Raue, Bernhard Steiert, Max Schelker et al. · Bioinformatics
Open access |
3 Jul 2015 |
270 |
| 11 |
An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation
Birgit Schoeberl, Anthony C. Faber, Danan Li et al. · Cancer Research
Open access |
9 Mar 2010 |
261 |
| 12 |
Effects of HER2 overexpression on cell signaling networks governing proliferation and migration
Alejandro Wolf‐Yadlin, Neil Kumar, Yi Zhang et al. · Molecular Systems Biology
Open access |
3 Oct 2006 |
256 |
| 13 |
Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism
Douglas J. Marcotte et al. · Bioorganic & Medicinal Chemistry
Open access |
19 Apr 2013 |
243 |
| 14 |
An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells
Qing Sheng, Xinggang Liu, ELEANOR M. FLEMING et al. · Cancer Cell
Open access |
Mar 2010 |
238 |
| 15 |
Profiling receptor tyrosine kinase activation by using Ab microarrays
Ulrik B. Nielsen, Mike H. Cardone, Anthony J. Sinskey et al. · Proceedings of the National Academy of Sciences
Open access |
22 Jul 2003 |
227 |
| 16 |
The Response of Human Epithelial Cells to TNF Involves an Inducible Autocrine Cascade
Kevin A. Janes, Suzanne Gaudet, John G. Albeck et al. · Cell
Open access |
Mar 2006 |
222 |
| 17 |
Viral contamination in biologic manufacture and implications for emerging therapies
Paul W. Barone et al. · Nature Biotechnology
Open access |
27 Apr 2020 |
215 |
| 18 |
Control of MAPK signalling: from complexity to what really matters
Jorrit J. Hornberg, Bernd R. Binder, Frank J. Bruggeman et al. · Oncogene
|
20 Jun 2005 |
204 |
| 19 |
Multiplexed sandwich assays in microarray format
Ulrik B. Nielsen, Bernhard H. Geierstanger · Journal of Immunological Methods
|
31 May 2004 |
200 |
| 20 |
Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion
Ashish V. Kalra, Jaeyeon Kim, Stephan G. Klinz et al. · Cancer Research
|
2 Oct 2014 |
198 |
| 21 |
Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Ramesh K. Ramanathan, Ronald Lee Korn, Natarajan Raghunand et al. · Clinical Cancer Research
|
3 Feb 2017 |
178 |
| 22 |
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma
Antoni Ribas, Theresa Medina, John M. Kirkwood et al. · Cancer Discovery
Open access |
29 Jul 2021 |
175 |
| 23 |
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
Kathy D. Miller, Javier Cortés, Sara A. Hurvitz et al. · BMC Cancer
Open access |
3 Jun 2016 |
167 |
| 24 |
A Compendium of Signals and Responses Triggered by Prodeath and Prosurvival Cytokines
Suzanne Gaudet, Kevin A. Janes, John G. Albeck et al. · Molecular & Cellular Proteomics
Open access |
19 Jul 2005 |
162 |
| 25 |
Fractional killing arises from cell‐to‐cell variability in overcoming a caspase activity threshold
Jérémie Roux, Marc A. Hafner, Samuel Bandara et al. · Molecular Systems Biology
Open access |
May 2015 |
151 |
| 26 |
Effects of Bcl-2 Levels on Fas Signaling-Induced Caspase-3 Activation: Molecular Genetic Tests of Computational Model Predictions
Fei Hua, Melanie Cornejo, Michael H. Cardone et al. · The Journal of Immunology
Open access |
Jul 2005 |
140 |
| 27 |
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study
Pamela N. Münster, Ian E. Krop, Patricia Mucci LoRusso et al. · British Journal of Cancer
Open access |
Oct 2018 |
134 |
| 28 |
Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer
Christopher W. Espelin, Shannon Curtis Leonard, Elena Geretti et al. · Cancer Research
|
13 Jan 2016 |
134 |
| 29 |
Effects of insulin-like growth factor-1 and dexamethasone on cytokine-challenged cartilage: relevance to post-traumatic osteoarthritis
Y. Li, Yan Wang, Susan Chubinskaya et al. · Osteoarthritis and Cartilage
Open access |
10 Nov 2014 |
126 |
| 30 |
HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity
Joseph G. Reynolds, Elena Geretti, Bart S. Hendriks et al. · Toxicology and Applied Pharmacology
|
21 Apr 2012 |
123 |
| 31 |
Driving the Model to Its Limit: Profile Likelihood Based Model Reduction
Tim Maiwald, Helge Hass, Bernhard Steiert et al. · PLoS ONE
Open access |
2 Sep 2016 |
111 |
| 32 |
Canine spontaneous glioma: A translational model system for convection-enhanced delivery
Peter J. Dickinson, Richard A. LeCouteur, Robert Higgins et al. · Neuro-Oncology
Open access |
20 May 2010 |
110 |
| 33 |
Shear- and Compression-induced Chondrocyte Transcription Requires MAPK Activation in Cartilage Explants
Jonathan B. Fitzgerald, Moonsoo M. Jin, Diana H. Chai et al. · Journal of Biological Chemistry
Open access |
18 Dec 2007 |
110 |
| 34 |
Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery
Huang‐Chiao Huang, Imran Rizvi, Joyce Liu et al. · Cancer Research
Open access |
29 Nov 2017 |
108 |
| 35 |
Computational Modeling of ERBB2 -Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors
Daniel C. Kirouac, Jin Du, Johanna Lahdenranta et al. · Science Signaling
|
13 Aug 2013 |
107 |
| 36 |
Single-Cell Quantitative HER2 Measurement Identifies Heterogeneity and Distinct Subgroups within Traditionally Defined HER2-Positive Patients
Matthew Onsum, Elena Geretti, Violette B. Paragas et al. · American Journal Of Pathology
Open access |
11 Sep 2013 |
107 |
| 37 |
MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors
Jonathan B. Fitzgerald, Bryan W. Johnson, Jason Baum et al. · Molecular Cancer Therapeutics
|
27 Nov 2013 |
103 |
| 38 |
Profiles of Basal and Stimulated Receptor Signaling Networks Predict Drug Response in Breast Cancer Lines
Mario Niepel, Marc A. Hafner, Emily A. Pace et al. · Science Signaling
Open access |
24 Sep 2013 |
102 |
| 39 |
Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression
Min H. Kang, Jing Wang, Monish Ram Makena et al. · Clinical Cancer Research
|
Mar 2015 |
102 |
| 40 |
Competing Docking Interactions can Bring About Bistability in the MAPK Cascade
Stefan Legewie, Birgit Schoeberl, Nils Blüthgen et al. · Biophysical Journal
Open access |
25 May 2007 |
96 |
| 41 |
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
Jodi A. McKenzie et al. · JNCI Journal of the National Cancer Institute
Open access |
27 Nov 2017 |
93 |
| 42 |
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
Sabrina Arena, Giulia Siravegna, Benedetta Mussolin et al. · Science Translational Medicine
Open access |
3 Feb 2016 |
93 |
| 43 |
Combining guilt-by-association and guilt-by-profiling to predict Saccharomyces cerevisiaegene function
Weidong Tian, Lan V. Zhang, Murat Taşan et al. · Genome biology
Open access |
27 Jun 2008 |
93 |
| 44 |
A comparison of specific space diversity techniques for reduction of fast fading in UHF mobile radio systems
William C. Jakes · IEEE Transactions on Vehicular Technology
|
Nov 1971 |
92 |
| 45 |
Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: “Drug Products, Including Biological Products, that Contain Nanomaterials”
Jon S. B. de Vlieger, Daan J.A. Crommelin, Katherine M. Tyner et al. · The AAPS Journal
Open access |
17 Apr 2019 |
91 |
| 46 |
Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts
Pin Yuan Chen, Tomoko Ozawa, Daryl C. Drummond et al. · Neuro-Oncology
Open access |
21 Dec 2012 |
90 |
| 47 |
Birth-Death and Bug Counting
W. Kremer · IEEE Transactions on Reliability
|
Apr 1983 |
84 |
| 48 |
Network topology and parameter estimation: from experimental design methods to gene regulatory network kinetics using a community based approach
Pablo Meyer, Thomas Cokelaer, Deepak Chandran et al. · BMC Systems Biology
Open access |
2014 |
80 |
| 49 |
A novel screening method to assess developability of antibody-like molecules
Neeraj Kohli, Neha Jain, Melissa L. Geddie et al. · mAbs
Open access |
11 May 2015 |
77 |
| 50 |
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)
Birgit Schoeberl et al. · npj Systems Biology and Applications
Open access |
5 Jan 2017 |
76 |